International Clinical Trial: Efficacy and Safety of Donafenib Plus Iparomlimab and Tuvonralimab Combined with Capecitabine in Postoperative Adjuvant Treatment for Biliary Tract Malignancies

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131377) titled 'Efficacy and Safety of Donafenib Plus Iparomlimab and Tuvonralimab Combined with Capecitabine in Postoperative Adjuvant Treatment for Biliary Tract Malignancies' on Sept. 1.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Affiliated Hospital of North Sichuan Medical College

Condition: Biliary tract malignancies include gallbladder carcinoma, intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma and distal cholangiocarcinoma.

Intervention: Trial group:Capecitabine, initiated on C1D1, 1250 mg/m^2 PO BID, days 1-14, every 3 weeks for up to 8 cycles Tondafarnib tosylate tablets,...